Drug Profile
Docetaxel intratumoural - LIDDS
Alternative Names: Nanodotax; NanoZolid®-docetaxel; NZ DTX; NZ-DTX DepotLatest Information Update: 26 Feb 2024
Price :
$50
*
At a glance
- Originator LIDDS
- Class Antineoplastics; Radiopharmaceutical diagnostics; Small molecules; Taxanes
- Mechanism of Action Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Non-small cell lung cancer
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 23 Feb 2024 LIDDS plans a DTX-002 clinical study for Solid tumours
- 04 Apr 2023 Docetaxel intratumoural is still in phase I development in Solid tumours (Late-stage disease) in Sweden, Lithuania and Denmark (Intratumoural, Injection) (LIDDS pipeline, April 2023)
- 08 Jul 2022 LIDDS has patent protection for NanoZolid® production process in Israel